Skip to content

Vitagnus effect on premenstrual symptoms

Evaluate the effect of Vitagnus on premenstrual syndrome in female students of Shahid Chamran dormitory

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014102219632N1
Enrollment
72
Registered
2015-02-04
Start date
2015-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrome. Unspecified condition associated with female genital organs and menstrual cycle

Interventions

Intervention 1: Five finger test group oral drops to 40 drops a day for three menstrual cycles. Intervention 2: A placebo control group, the intervention takes place.
Treatment - Drugs
Placebo
Five finger test group oral drops to 40 drops a day for three menstrual cycles
A placebo control group, the intervention takes place

Sponsors

Ahvaz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: students with premenstrual syndrome with regular menstrual cycle. exclusion criteria: Psychotherapy with pregnancy or breastfeeding; use of hormones; stress in the recent quarter such as marriage or the death of someone close surgery; patients taking certain medications such as dopamine antagonists used

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The severity of the symptoms of premenstrual syndrome. Timepoint: one? two Three months after intervention. Method of measurement: Recorded daily symptoms of PMS.

Secondary

MeasureTime frame
Side effects include itching, dizziness, stomach pain, diarrhea. Timepoint: Two weeks until 1 mounth. Method of measurement: Phone calls and monthly views.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvaneh Mousavi

Ahvaz University of Medical Sciences

mousavi-p@ajums.ac.ir+98 917 480 0362

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026